Sarepta Therapeutics Inc. elected Michael Bonney to its board of directors.
Bonney was the CEO of Cubist Pharmaceuticals, up until its acquisition by Merck & Co. Inc. in 2014. He is the CEO and chair of Kaleido Biosciences. He also serves as chair of the boards of Alnylam Pharmaceuticals Inc. and Magenta Therapeutics.
